Twist Bioscience Corporation (TWST) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Diagnostics & Research) last closed at $188.67. The rating moved from Neutral to Overbought on September 29, 2026.

• Public ratingOverbought (as of October 3, 2026)
• Last close$188.67
• Last changeMoved from Neutral to Overbought on September 29, 2026
• SectorHealthcare
• IndustryDiagnostics & Research

See all overbought Healthcare stocks →

AI analysis

Twist Bioscience benefits from a differentiated, scalable DNA synthesis technology and sits at the intersection of multiple growing end markets (therapeutics, diagnostics, and synthetic biology). Revenue growth potential is supported by increasing commercial adoption and planned capacity expansion, but the company remains loss-making with capital needs that could lead to dilution. Near-term performance will be sensitive to execution on manufacturing scale-up, timing of large customer orders, and broader market sentiment toward biotech. Balanced upside comes with material execution and financing risks; monitor cash runway, margin progression, customer diversification, and any strategic partnerships as primary catalysts or warning signs.

Key factors

• Proprietary silicon-based DNA synthesis platform that offers scale, speed and lower per-base cost vs traditional methods
• Addressable market expansion driven by growth in synthetic biology, mRNA therapeutics, gene and cell therapy, diagnostics and agricultural biotech
• Momentum in commercial adoption from pharma/biotech customers and recurring demand for custom oligonucleotides and longer DNA constructs
• Capacity expansion initiatives that should enable higher revenue throughput if execution remains on plan
• Positive sector-level appetite for select specialty biotech and late-stage biologics, which can support collaboration and partnership activity

Risks

• Ongoing net losses and cash burn could require capital raises that dilute existing shareholders or add financing cost
• Customer concentration and contract timing can create lumpy revenue and near-term volatility in reported results
• Competition from established reagent suppliers and new synthetic-biology entrants that may pressure pricing and margins
• Execution risk on scale-up of manufacturing capacity and maintaining product reliability/quality at higher volumes
• Macroeconomic risk and risk-off market sentiment that can depress valuations and slow partner/customer R&D spending
• Regulatory or supply-chain disruptions that could delay customer programs or constrain throughput

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.